Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for 23andMe Holding Co. (MEHCQ : OTC)

• Company Description    23andMe Inc. is a consumer genetics and research company. It involved in discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory and cardiovascular diseases, in addition to other therapeutic areas. 23andMe Inc., formerly known as VG Acquisition Corp., is headquartered in Sunnyvale, CA. Number of Employees: 265

• Price / Volume Information    Yesterday's Closing Price: $4.04 Daily Weekly Monthly 20 Day Moving Average: 69,966 shares Shares Outstanding: 27.54 (millions) Market Capitalization: $111.27 (millions) Beta: 2.13 52 Week High: $6.21 52 Week Low: $0.26 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 6.32% 4.45% 12 Week -9.62% -17.90% Year To Date 24.31% 7.97%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 870 MARKET STREET ROOM 415 - SAN FRANCISCO,CA 94102 USA ph: 650-938-6300 fax: - investors@23andme.com http://www.23andme.com

• General Corporate Information    Officers Joseph Selsavage - Chief Executive Officer and Chief Financial and Ac Mark Jensen - Chairman Andre Fernandez - Director Jim Frankola - Director Thomas Walper - Director Peer Information 23andMe Holding Co. (CORR.) 23andMe Holding Co. (RSPI) 23andMe Holding Co. (CGXP) 23andMe Holding Co. (BGEN) 23andMe Holding Co. (GTBP) 23andMe Holding Co. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 90138Q306 SIC: 2834 Fiscal Year Fiscal Year End: March Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/11/25 Share - Related Items Shares Outstanding: 27.54 Most Recent Split Date: 10.00 (0.05:1) Beta: 2.13 Market Capitalization: $111.27 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 0.64 EPS Growth vs. Year Ago Period: 68.93% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -37.10% vs. Previous Quarter: -43.70% ROE 06/30/25 - -827.24 03/31/25 - -344.18 12/31/24 - -170.07 ROA 06/30/25 - -87.31 03/31/25 - -86.15 12/31/24 - -62.13 Current Ratio 06/30/25 - 0.81 03/31/25 - 1.41 12/31/24 - 1.05 Quick Ratio 06/30/25 - 0.69 03/31/25 - 1.20 12/31/24 - 0.91 Operating Margin 06/30/25 - -112.39 03/31/25 - -127.51 12/31/24 - -101.15 Net Margin 06/30/25 - -130.25 03/31/25 - -143.97 12/31/24 - -183.39 Pre-Tax Margin 06/30/25 - -116.70 03/31/25 - -123.88 12/31/24 - -132.06 Book Value 06/30/25 - -1.56 03/31/25 - -0.97 12/31/24 - 2.35 Inventory Turnover 06/30/25 - 5.01 03/31/25 - 5.40 12/31/24 - 6.32 Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - 0.00

Powered by Zacks Investment Research ©